6 completed, 4 recruiting, 2 withdrawn. 10 Phase 2, 2 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Completed 6, Recruiting 4 |
| Phase 4 | 2 | Withdrawn 2 |
Follow Alto Neuroscience: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ALTO-207 in Adults With Treatment-resistant Depression (TRD) ALTO-207, Placebo - Treatment-resistant Depression (TRD) | Phase 2 | Recruiting | Alto Neuroscience | 178 | 2026-05-20 | 2026-10-26 |
| ALTO-100 in Bipolar Disorder With Depression (BD-D) ALTO-100, Placebo - Bipolar Disorder I or II With a Major Depressive Episode | Phase 2 | Recruiting | Alto Neuroscience | 200 | 2024-10-02 | 2026-10-13 |
| Study of ALTO-101 in Patients With Schizophrenia ALTO-101, ALTO-101 Transdermal Delivery System, Placebo - Schizophrenia, Cognitive Impairment | Phase 2 | Recruiting | Alto Neuroscience | 82 | 2024-06-11 | 2025-12-26 |
| PD, PK, and Safety of ALTO-203 in Patients With MDD ALTO-203 25 μg, ALTO-203 75 μg, Placebo - Major Depressive Disorder, Anhedonia | Phase 2 | Completed | Alto Neuroscience | 69 | 2024-03-25 | 2026-04-17 |
| Study of ALTO-300 in MDD ALTO-300, Placebo - Major Depressive Disorder | Phase 2 | Recruiting | Alto Neuroscience | 325 | 2023-06-08 | 2026-10-26 |
| Phase 2b Study of ALTO-100 in MDD ALTO-100, Placebo - Major Depressive Disorder | Phase 2 | Completed | Alto Neuroscience | 301 | 2023-01-10 | 2025-09-08 |
| Pilot Decentralized Trial ALTO-100 PO Tablet - Major Depressive Disorder | Phase 2 | Completed | Alto Neuroscience | 21 | 2022-06-01 | 2024-01-18 |
| ALTO-300 in Depression (ALTO-300-004) ALTO-300 PO Tablet - Major Depressive Disorder | Phase 2 | Completed | Alto Neuroscience | 148 | 2022-02-03 | 2024-04-26 |
| ALTO-100 in MDD and/or PTSD ALTO-100 PO tablet - Major Depressive Disorder, Post Traumatic Stress Disorder | Phase 2 | Completed | Alto Neuroscience | 245 | 2021-12-20 | 2023-12-01 |
| ALTO-300 in Depression ALTO-300 oral (PO) tablet - Major Depressive Disorder | Phase 2 | Completed | Alto Neuroscience | 91 | 2021-12-13 | 2024-04-30 |
| Leveraging EEG for Antidepressant Prediction With Sertraline and Escitalopram Sertraline, Escitalopram - Major Depressive Disorder | Phase 4 | Withdrawn | Alto Neuroscience | 2020-10-15 | 2020-10-19 | |
| Leveraging EEG for Antidepressant Prediction With Duloxetine and Bupropion Duloxetine, Bupropion - Major Depressive Disorder | Phase 4 | Withdrawn | Alto Neuroscience | 2020-10-15 | 2020-10-19 |
Depressive Disorder, Major (9) · Anhedonia (1) · Cognitive Dysfunction (1) · Depressive Disorder, Treatment-Resistant (1) · Schizophrenia (1) · Stress Disorders, Post-Traumatic (1)
Bupropion (1) · Duloxetine Hydrochloride (1) · Escitalopram (1) · Sertraline (1) · Tablets (1)
United States (10) · United Kingdom (2)
Adam Savitz, MD, PhD (2) · Corey Keller, MD, PhD (2)
R44MH123373 (1)